Quick Answer
Tango Therapeutics, Inc. reported Cash and Equivalents of $112.28 million for fiscal year 2025.
Tango Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $112.28M | +61.5% |
| 2024 | $69.53M | +4.7% |
| 2023 | $66.39M | +10.7% |
| 2022 | $59.97M | -58.0% |
| 2021 | $142.75M | +403.0% |
| 2020 | $28.38M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $58.34M | +9.8% | +48.5% |
| June 30, 2025 | $39.27M | -23.8% | -32.8% |
| March 31, 2025 | $58.43M | -4.5% | -16.0% |
| December 31, 2024 | $69.53M | +4.7% | +30.8% |
| September 30, 2024 | $53.15M | -9.2% | +3.1% |
| June 30, 2024 | $51.57M | -21.9% | -15.7% |
| March 31, 2024 | $61.16M | +6.8% | -7.9% |
| December 31, 2023 | $66.39M | +10.7% | +13.4% |
- Tango Therapeutics, Inc. showed an increase of +61.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Tango Therapeutics, Inc.’s cash and equivalents has grown by 295.6% (from $28.38 million to $112.28 million).
- The most recent figure is from Tango Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: